Treace Medical Concepts (NASDAQ:TMCI) Announces Quarterly Earnings Results

Treace Medical Concepts (NASDAQ:TMCI - Get Free Report) released its earnings results on Thursday. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.03, Zacks reports. The company had revenue of $68.71 million during the quarter, compared to the consensus estimate of $67.19 million. Treace Medical Concepts had a negative return on equity of 51.12% and a negative net margin of 30.33%. Treace Medical Concepts updated its FY 2025 guidance to EPS.

Treace Medical Concepts Stock Down 2.1 %

Shares of NASDAQ:TMCI traded down $0.19 on Friday, hitting $8.94. 847,173 shares of the company's stock were exchanged, compared to its average volume of 729,188. The firm's 50-day moving average is $8.91 and its 200 day moving average is $7.24. The company has a market capitalization of $556.94 million, a PE ratio of -9.03 and a beta of 0.75. Treace Medical Concepts has a 1-year low of $3.92 and a 1-year high of $13.80. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.98 and a current ratio of 4.12.

Analyst Upgrades and Downgrades

TMCI has been the subject of a number of research reports. Stifel Nicolaus lifted their price objective on shares of Treace Medical Concepts from $7.00 to $8.00 and gave the company a "hold" rating in a report on Wednesday, November 6th. BTIG Research upgraded shares of Treace Medical Concepts from a "neutral" rating to a "buy" rating and set a $16.00 price target for the company in a research note on Tuesday, February 4th. JPMorgan Chase & Co. restated a "neutral" rating and issued a $8.00 price target on shares of Treace Medical Concepts in a research note on Tuesday, December 17th. Lake Street Capital started coverage on Treace Medical Concepts in a research note on Tuesday, December 31st. They set a "buy" rating and a $14.50 target price for the company. Finally, Truist Financial boosted their target price on Treace Medical Concepts from $7.00 to $8.40 and gave the stock a "hold" rating in a research note on Wednesday, December 18th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $9.99.

Treace Medical Concepts Company Profile

Treace Medical Concepts, Inc, a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity.